DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Obiltoxaximab
Obiltoxaximab
Where Do Novel Drugs of 2016 Fit In?
CDER Therapeutic Biologic Products List
Studies on Antitoxin Use for Postexposure Prophylaxis (PEP)
ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 Is Available in Electronic Format on the PMPRB Website
Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current Challenges & Perspectives March 31 - April 1, 2016
125509Orig1s000
125509 Obiltoxaximab Statistical PREA
Medizinische Biotechnologie in Deutschland 2021
(INN) for Biological and Biotechnological Substances
Protein Complexes
List Item Obiltoxaximab
Development and Challenges to Monoclonal Antibodies for Passive Immunization
Public Summary of Opinion on Orphan Designation Obiltoxaximab for the Treatment of Anthrax
Supporting Information
International Nonproprietary Names for Pharmaceutical Substances (INN)
Development of Therapeutic Antibodies for the Treatment Of
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2018
Assessment Report
Top View
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Human Medicines Highlights 2020 Authorisation of New Medicines
2016 NOVEL DRUGS Summary
125509 Obiltoxaximab Clinpharm PREA
Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Antibiotics in the Clinical Pipeline in October 2019
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Antibody News You Should Know July 1 - 15, 2020
AHFS Pharmacologic-Therapeutic Classification System
Biologics and Biosimilars: Background and Key Issues
Biological Product Deviation Reporting and HCT/P Deviation Reporting – Non-Blood Product Codes
(INN) for Biological and Biotechnological Substances
New FDA Approved Antibacterial Drugs: 2015-2017
Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule
ESCMID Online Lecture Library © by Author
ANTHIM (Obiltoxaximab) Injection
Development of Antibody Therapeutics Against Flaviviruses
Developments in Therapy with Monoclonal Antibodies and Related Proteins
Biologics and Biosimilars: Background and Key Issues
Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives
Monoclonal Antibodies